Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's rare endocrine franchise includes RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing's syndrome, and veldoreotide extended release, a preclinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company's rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.
Company profile
Ticker
SBBP
Exchange
Website
CEO
Matthew Pauls
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cortendo AB
SEC CIK
Corporate docs
Subsidiaries
Strongbridge U.S. Inc. • Strongbridge Dublin Limited • Cortendo AB ...
SBBP stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
15 Oct 21
EFFECT
Notice of effectiveness
7 Oct 21
EFFECT
Notice of effectiveness
7 Oct 21
EFFECT
Notice of effectiveness
7 Oct 21
25-NSE
Exchange delisting
5 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 21
Transcripts
SBBP
Earnings call transcript
2021 Q1
12 May 21
SBBP
Earnings call transcript
2020 Q4
3 Mar 21
SBBP
Earnings call transcript
2020 Q3
31 Oct 20
SBBP
Earnings call transcript
2020 Q2
4 Aug 20
SBBP
Earnings call transcript
2020 Q1
10 May 20
SBBP
Earnings call transcript
2019 Q4
25 Feb 20
SBBP
Earnings call transcript
2019 Q3
7 Nov 19
SBBP
Earnings call transcript
2019 Q2
31 Jul 19
SBBP
Earnings call transcript
2019 Q1
1 May 19
SBBP
Earnings call transcript
2018 Q4
26 Feb 19
Latest ownership filings
SC 13G/A
ORBIMED ADVISORS LLC
11 Feb 22
SC 13D/A
CAXTON CORP
5 Jan 22
4
Bruce Kovner
5 Jan 22
SC 13D/A
Growth Equity Opportunities Fund III, LLC
25 Oct 21
4
Scott L. Wilhoit
6 Oct 21
4
Richard S Kollender
6 Oct 21
4
Fredric J. Cohen
6 Oct 21
4
JOHN JOHNSON
6 Oct 21
4
Hilde H Steineger
6 Oct 21
4
Marten Steen
6 Oct 21
Financial summary
| Quarter (USD) | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 63.77 mm | 63.77 mm | 63.77 mm | 63.77 mm | 63.77 mm | 63.77 mm |
| Cash burn (monthly) | 3.37 mm | (no burn) | 4.41 mm | 3.88 mm | 3.28 mm | 2.83 mm |
| Cash used (since last report) | 64.75 mm | n/a | 84.67 mm | 74.50 mm | 62.85 mm | 54.33 mm |
| Cash remaining | -972.64 k | n/a | -20.90 mm | -10.73 mm | 926.78 k | 9.45 mm |
| Runway (months of cash) | -0.3 | n/a | -4.7 | -2.8 | 0.3 | 3.3 |
Institutional ownership, Q4 2021
5.6% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 1 |
| Opened positions | 0 |
| Closed positions | 49 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 9.24 mm |
| Total shares | 3.80 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| HealthCap VI | 3.80 mm | $9.24 mm |
| Orbimed Advisors | 0.00 | $0.00 |
| Caxton | 0.00 | $0.00 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 5 Oct 21 | Steen Marten | Ordinary Shares | Sale back to company | Dispose D | Yes | No | 0 | 64,151 | 0.00 | 0 |
| 5 Oct 21 | Steen Marten | Stock Option Ordinary Shares | Sale back to company | Dispose D | Yes | No | 0 | 154,918 | 0.00 | 0 |
| 5 Oct 21 | Jeffrey W Sherman | Ordinary Shares | Sale back to company | Dispose D | No | No | 0 | 64,258 | 0.00 | 0 |
| 5 Oct 21 | Jeffrey W Sherman | Stock Option Ordinary Shares | Sale back to company | Dispose D | No | No | 0 | 140,000 | 0.00 | 0 |
| 5 Oct 21 | Kong Garheng | Ordinary Shares | Sale back to company | Dispose D | No | No | 0 | 63,993 | 0.00 | 0 |
| 5 Oct 21 | Kong Garheng | Stock Option Ordinary Shares | Sale back to company | Dispose D | No | No | 0 | 154,385 | 0.00 | 0 |
| 5 Oct 21 | Gill David N | Ordinary Shares | Sale back to company | Dispose D | No | No | 0 | 78,058 | 0.00 | 0 |
| 5 Oct 21 | Stephen J Long | Ordinary Shares | Sale back to company | Dispose D | No | No | 0 | 117,793 | 0.00 | 0 |
| 5 Oct 21 | Stephen J Long | Stock Option Ordinary Shares | Sale back to company | Dispose D | No | No | 0 | 714,045 | 0.00 | 0 |